Cyclacel Pharmaceuticals, Inc. (CYCCP)
Cyclacel Pharmaceuticals, Inc.
200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
United States
908 517 7330
https://www.cyclacel.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Spiro George Rombotis | President, CEO & Executive Director | 612.47k | N/A | 1959 |
| Mr. Paul McBarron | Executive VP of Finance, CFO, COO, Secretary & Executive Director | 321.61k | N/A | 1961 |
| Ms. Gill Christie | Director of Human Resources | N/A | N/A | 1957 |
| Dr. Brian Schwartz M.D. | Interim Chief Medical Officer & Director | 51k | N/A | 1963 |
| Grace Kim | Investor Relations Executive | N/A | N/A | N/A |
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Corporate governance
Cyclacel Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
